The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Novartis to Pay $390 Million in U.S. Settlement over Pharmacy Kickbacks

Novartis to Pay $390 Million in U.S. Settlement over Pharmacy Kickbacks

November 24, 2015 • By Sarah N. Lynch

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON (Reuters)—Novartis Pharmaceuticals Corp. will pay $390 million to settle U.S. charges that it paid specialty pharmacies illegal kickbacks in exchange for inducing patients to refill certain medications, according to an accord announced Friday.

You Might Also Like
  • Pfizer Unit to Pay $784.6 Million in Medicaid Rebate Settlement
  • CVS to Pay $5 Million to Resolve U.S. Drug Probe
  • Novartis Signs $170 Million Immuno-Oncology Pact with Surface

The settlement between a U.S. unit of Swiss drugmaker Novartis AG, the federal government and more than 40 states concerns payments that the drug manufacturer paid between 2007–2012 to certain specialty pharmacies to entice them to recommend prescriptions to Medicaid and Medicare patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The federal part of the case, brought by the U.S. Attorney for the Southern District of New York, involved six drugs including iron-reducing Exjade and immunosuppressant Myfortic.

In the settlement, Novartis admitted to a series of facts detailing its relationship with specialty pharmacies and how the alleged scheme worked.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The company said it’s implementing new controls to help strengthen its arrangements with specialty pharmacies, and that it is “committed to high standards of ethical business conduct.”

Specialty pharmacies typically dispense medications that are more costly, or require special handling.

The sector has come under intense scrutiny in recent months, after drug manufacturer Valeant Pharmaceuticals International Inc. was forced to sever ties with specialty pharmacy Philidor over questions about Philidor’s billing practices and business relationship with Valeant.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Novartis case was sparked by David Kester, a former sales manager who filed a whistleblower complaint under the False Claims Act—a law that permits non-government employees to file actions on behalf of the government.

Prosecutors say that Novartis selected certain specialty pharmacies to be part of a closed distribution network called EPASS, which was used to fill prescriptions.

The pharmacies were then asked to urge patients to continue taking the drug and downplay its risks and side effects.

Novartis also ran a contest and kept “score cards” on which pharmacy kept patients on certain drugs for the longest period of time.

“I believe many of my customers, who were the physicians and nurses treating patients with life-threatening diseases, did not fully understand the relationships between the specialty pharmacies and Novartis,” Kester told Reuters in written responses to questions.

Two of the pharmacies in the case—Accredo Health Group Inc., a unit of Medco Health Solutions, and BioScrip Inc.—previously settled charges and collectively paid $75 million.

Kester’s attorney Shelley Slade said the case marks the largest-ever recovery to the government from a False Claims Act lawsuit based solely on a kickback theory.

Filed Under: Drug Updates, Pharma Co. News Tagged With: False Claims Act, fraud, Legal, Novartis, pharmacy

You Might Also Like:
  • Pfizer Unit to Pay $784.6 Million in Medicaid Rebate Settlement
  • CVS to Pay $5 Million to Resolve U.S. Drug Probe
  • Novartis Signs $170 Million Immuno-Oncology Pact with Surface
  • U.S. Probes Contracts Between Drugmakers, Pharmacy Benefit Managers

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)